2022. Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s29. DOI:https://doi.org/10.25251/skin.6.supp.s29.